As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
15 Analysts have issued a Celcuity Inc. forecast:
15 Analysts have issued a Celcuity Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -146 -146 |
72%
72%
|
|
| EBIT (Operating Income) EBIT | -147 -147 |
72%
72%
|
|
| Net Profit | -149 -149 |
80%
80%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
| Head office | United States |
| CEO | Brian Sullivan |
| Employees | 87 |
| Founded | 2012 |
| Website | www.celcuity.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


